A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
Volume: 24, Issue: S1, Pages: 103 - 111
Published: Feb 18, 2020
Abstract
Dotinurad is a novel, selective urate reabsorption inhibitor (SURI), which reduces serum uric acid levels by selective inhibition of the urate transporter 1 (URAT1). The Japanese guideline for the management of hyperuricemia and gout recommends that drug selection should be based on classification of hyperuricemia as a fundamental principle. However, there may be some cases where this principle is not observed. We investigated the...
Paper Details
Title
A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
Published Date
Feb 18, 2020
Volume
24
Issue
S1
Pages
103 - 111
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History